Your browser is no longer supported. Please, upgrade your browser.
Settings
GBT Global Blood Therapeutics, Inc. daily Stock Chart
GBT [NASD]
Global Blood Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.03 Insider Own4.70% Shs Outstand55.81M Perf Week4.99%
Market Cap2.35B Forward P/E- EPS next Y-4.03 Insider Trans-2.27% Shs Float49.54M Perf Month-10.91%
Income-135.20M PEG- EPS next Q-0.87 Inst Own98.30% Short Float9.62% Perf Quarter-12.67%
Sales- P/S- EPS this Y-11.30% Inst Trans12.37% Short Ratio6.29 Perf Half Y12.28%
Book/sh11.26 P/B3.73 EPS next Y-10.40% ROA-35.70% Target Price72.46 Perf Year43.76%
Cash/sh9.74 P/C4.32 EPS next 5Y37.00% ROE-38.70% 52W Range24.02 - 68.05 Perf YTD6.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-38.21% Beta-
Dividend %- Quick Ratio23.10 Sales past 5Y- Gross Margin- 52W Low75.03% ATR2.62
Employees147 Current Ratio23.10 Sales Q/Q- Oper. Margin- RSI (14)39.67 Volatility5.42% 5.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-45.90% Profit Margin- Rel Volume1.02 Prev Close41.35
ShortableYes LT Debt/Eq0.00 EarningsMay 07 Payout- Avg Volume757.47K Price42.05
Recom1.80 SMA20-8.96% SMA50-8.69% SMA200-5.69% Volume772,214 Change1.69%
May-08-18Reiterated SunTrust Buy $80 → $77
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-28-18Reiterated Cantor Fitzgerald Overweight $61 → $72
Feb-14-18Initiated Janney Buy
Jan-23-18Initiated William Blair Outperform
Dec-14-17Reiterated Needham Buy $51 → $70
Dec-01-17Initiated H.C. Wainwright Buy $73
Sep-21-17Initiated Needham Buy $51
Aug-08-17Reiterated JP Morgan Overweight $44 → $46
Apr-18-17Initiated SunTrust Buy $56
Mar-21-17Resumed Wedbush Outperform $73
Mar-16-17Initiated Cantor Fitzgerald Overweight $61
Mar-02-17Initiated Instinet Buy $50
Jan-04-17Initiated JP Morgan Overweight
Nov-01-16Initiated ROTH Capital Buy $47
Oct-25-16Reiterated Wedbush Outperform $66 → $73
Sep-30-16Initiated Wells Fargo Outperform
Mar-02-16Reiterated Wedbush Outperform $94 → $66
Sep-08-15Initiated Wedbush Outperform
Sep-08-15Initiated Morgan Stanley Overweight $67
Jun-21-18 11:04AM  3 Killer Stocks Trading at Unfair Discounts TheStreet.com
Jun-15-18 01:06PM  Here's Why Shares of Global Blood Therapeutics Inc Are Falling Today Motley Fool -14.88%
11:33AM  Global Blood Therapeutics Shares Plunge After Sickle Cell Candidate Shows Reduced Effect Benzinga
02:30AM  GBT Announces New Phase 2a Voxelotor Data in Adolescents with Sickle Cell Disease (SCD) at 23rd European Hematology Association (EHA) Congress GlobeNewswire
Jun-14-18 07:05AM  Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities ACCESSWIRE
Jun-13-18 02:55PM  Hematology Conference Could Spur Some of Biotech's Outperformers Bloomberg
Jun-08-18 08:30AM  GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease (SCD) Program at Foundation for Sickle Cell Disease Researchs 12th Annual Symposium GlobeNewswire
Jun-05-18 04:05PM  GBT Announces New Employment Inducement Grants GlobeNewswire
Jun-04-18 07:35AM  Consolidated Research: 2018 Summary Expectations for ManTech International, Rapid7, Global Blood Therapeutics, CONSOL Coal Resources LP, Ryanair, and Yandex N.V. Fundamental Analysis, Key Performance Indications GlobeNewswire
May-25-18 08:40AM  Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options Zacks
May-23-18 03:00AM  Stocks To Watch: Global Blood Therapeutic Sees RS Rating Jump To 83 Investor's Business Daily
May-19-18 10:00AM  Even Momentum Traders Should Study Stock Charts TheStreet.com
May-18-18 07:31PM  Global Blood Therapeutics Incs (NASDAQ:GBT) Profit Outlook Simply Wall St.
May-17-18 10:30AM  GBT Announces Upcoming Data Presentations Supporting Voxelotor Sickle Cell Disease Program at 23rd European Hematology Association (EHA) Congress GlobeNewswire
May-11-18 12:25PM  Having Some Good Luck With Biotech Names TheStreet.com +5.66%
May-09-18 01:52PM  Markets Make an Art of Unpredictability TheStreet.com
May-08-18 12:03PM  Markets Confused by Trump's Upcoming Iran Decision TheStreet.com +7.96%
May-07-18 04:58PM  Global Blood: 1Q Earnings Snapshot Associated Press
04:05PM  GBT Reports Recent Business Progress and First Quarter 2018 Financial Results GlobeNewswire
May-04-18 08:30AM  GBT Announces New Employment Inducement Grants GlobeNewswire
Apr-27-18 07:30AM  [$$] Biotechs Make Headway in Battle Against Sickle Cell Disease The Wall Street Journal
Apr-10-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Global Blood Therapeutics, Wix, Changyou, BT Group, Golar LNG, and NantHealth New Research Emphasizes Economic Growth GlobeNewswire +7.65%
Apr-03-18 04:05PM  GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
04:05PM  GBT Announces New Employment Inducement Grants GlobeNewswire
Mar-22-18 08:30AM  Todays Research Reports on Trending Tickers: Global Blood Therapeutics and Sangamo Therapeutics ACCESSWIRE
Mar-21-18 11:59AM  Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics Benzinga -5.00%
08:43AM  Why Global Blood Therapeutics (GBT) Could Be Positioned for a Slump Zacks
Mar-15-18 04:05PM  GBT Announces New Employment Inducement Grants GlobeNewswire
07:31AM  Better Know Biotech: 3 Highfliers That Ought to Be on Your Radar Motley Fool
Mar-14-18 08:10AM  Research Report Identifies Supernus Pharmaceuticals, Celestica, Global Blood Therapeutics, BioTime, CyberArk Software, and Tivity Health, Inc. with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-12-18 02:00PM  5 Stocks That Are Showing Signs of Reversing TheStreet.com -5.42%
08:00AM  Global Blood Therapeutics Announces Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-08-18 10:00PM  Global Blood Therapeutics Announces Pricing of Public Offering of 4,000,000 Shares of Common Stock GlobeNewswire -5.40%
07:23PM  Is Global Blood Therapeutics Incs (NASDAQ:GBT) Liquidity As Good As Its Solvency? Simply Wall St.
04:01PM  Global Blood Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-06-18 08:00AM  GBT Appoints Industry Leader David L. Johnson as Chief Commercial Officer GlobeNewswire
Mar-05-18 04:05PM  GBT Announces Participation at Upcoming Investor Conferences in March GlobeNewswire
04:05PM  GBT Announces New Employment Inducement Grants GlobeNewswire
Feb-28-18 05:04AM  Global Blood reports 4Q loss Associated Press
Feb-27-18 04:07PM  GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2017 Financial Results GlobeNewswire
08:07AM  This could be the next $1 billion drug, if patients get on board MarketWatch
Feb-15-18 10:47AM  With an Eye on Biotech, Here's Today's Trading Thesis TheStreet.com
Feb-07-18 04:05PM  GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference GlobeNewswire +6.04%
10:53AM  The Confidence in the Dip Buyers Has Weakened TheStreet.com
Feb-05-18 12:39PM  Here's Why Global Blood Therapeutics Inc. Soared 47.1% in January Motley Fool -5.06%
Jan-29-18 08:01AM  Novo Nordisk remains on hunt for biopharma deals Reuters
Jan-23-18 12:22PM  William Blair Values Global Blood Therapeutics' Stock At $80 Benzinga +6.12%
Jan-13-18 10:32AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jan-10-18 10:31AM  Selling Action Is Upon Us TheStreet.com +17.60%
Jan-09-18 01:13PM  Healthcare Stocks Breakout: Pain Therapeutics, Inc. (PTIE), Global Blood Therapeutics Inc (GBT) SmarterAnalyst +19.07%
12:35PM  Why Global Blood Therapeutics Inc Is Rising Today Motley Fool
08:00AM  GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD) GlobeNewswire
Jan-03-18 04:05PM  GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-22-17 09:00AM  GBT Appoints Wendy L. Yarno to Board of Directors GlobeNewswire
Dec-15-17 09:03AM  Global Blood Therapeutics Prices a $100.0 Million Common Stock Public Offering GlobeNewswire -7.99%
Dec-14-17 04:01PM  Global Blood Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Dec-12-17 04:59PM  Why This Biotech Stock Is Defying A Hematology-Related Pitfall Investor's Business Daily -14.24%
03:42PM  This Is Why Global Blood Therapeutics Inc. Is Sinking Today Motley Fool
11:24AM  Is Global Blood Therapeutics Incs (undefined:GBT) CEO Overpaid Relative To Its Peers? Simply Wall St.
Dec-11-17 02:25PM  Life-Shortening Blood Disease Gets Rush of Research Bloomberg
10:12AM  Morgan Stanley: Global Blood Therapeutics 'Clearly Encouraged' By Sickle Cell Therapy Data Benzinga
07:00AM  GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program GlobeNewswire
Dec-09-17 10:00AM  GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD) GlobeNewswire
Nov-30-17 04:05PM  Global Blood Therapeutics Announces New Employment Inducement Grants GlobeNewswire +5.48%
03:42PM  Global Blood Therapeutics, Inc. Fundamental Analysis : November 30, 2017 Capital Cube
Nov-13-17 08:00AM  Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease GlobeNewswire
Nov-07-17 04:05PM  Global Blood Therapeutics Announces Participation at the Stifel 2017 Healthcare Conference GlobeNewswire -6.35%
Nov-03-17 12:43PM  Markets Get Back to Business as Usual TheStreet.com +6.27%
Nov-02-17 07:00PM  Global Blood reports 3Q loss Associated Press
04:05PM  Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results GlobeNewswire
Nov-01-17 09:00AM  Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Oct-30-17 05:10PM  Global Blood Therapeutics Inc. Jumped as Much as 14% on This News Motley Fool +12.52%
Oct-28-17 02:15PM  Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient with Severe and Symptomatic Anemia GlobeNewswire
Oct-24-17 08:00AM  Global Blood Therapeutics Announces Approval of First-in-Class Voxelotor as Nonproprietary Name for GBT440 GlobeNewswire
06:51AM  Global Blood Therapeutics stock declines after forsaking half its drug pipeline MarketWatch
Oct-23-17 09:15AM  DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers TheStreet.com
07:24AM  Global Blood Therapeutics stock drops 11.5% after discontinuation of pulmonary fibrosis therapy MarketWatch
Oct-11-17 08:00AM  Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype GlobeNewswire
Oct-05-17 03:00AM  Global Blood Therapeutic Earns Relative Strength Rating Upgrade Investor's Business Daily
Oct-04-17 01:08PM  Steven Cohen Doubles Down on Sickle Cell Disease Therapeutics Company Global Blood GuruFocus.com +8.92%
Oct-03-17 08:00AM  Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October GlobeNewswire
Sep-26-17 04:05PM  Global Blood Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Sep-21-17 10:21AM  One Thing To Consider Before Buying Global Blood Therapeutics Inc (GBT) Simply Wall St. -5.07%
Sep-14-17 03:00AM  Global Blood Therapeutic Sees IBD RS Rating Climb To 71 Investor's Business Daily
Sep-06-17 08:00AM  Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference GlobeNewswire
Sep-05-17 08:00AM  Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD) GlobeNewswire -6.27%
Aug-30-17 04:05PM  Global Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September GlobeNewswire
Aug-09-17 04:05PM  Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-07-17 11:57PM  Global Blood reports 2Q loss Associated Press
04:05PM  Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results GlobeNewswire
Jul-26-17 04:05PM  Global Blood Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Jul-10-17 08:00AM  Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population GlobeNewswire
Jul-03-17 08:31AM  Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options Zacks +5.30%
Jun-28-17 09:29AM  Global Blood Shares Pop on Priority Designation; Kite Pharma Rises on Patent News: Biotech Movers TheStreet.com +9.09%
08:31AM  Global Blood Therapeutics stock surges 5% on eligibility for European priority drug program MarketWatch
08:00AM  Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD) GlobeNewswire
Jun-23-17 02:30AM  Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease GlobeNewswire
Jun-06-17 04:05PM  Global Blood Therapeutics Announces Participation at the Goldman Sachs 38th Annual Global Healthcare Conference GlobeNewswire
May-18-17 04:00PM  Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Associations 22nd Congress GlobeNewswire
May-01-17 04:10PM  Global Blood reports 1Q loss Associated Press +6.22%
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is voxelotor, an oral once-daily therapy that modulates hemoglobin's affinity for oxygen, which is in Phase III clinical trials in adult and adolescent patients with sickle cell disease (SCD). The company is also involved in evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trials of adolescent and pediatric patients with SCD; and other research and development activities that are in pre-clinical phase. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Choi JungSee RemarksMay 17Option Exercise3.401,4004,760137,477May 21 04:36 PM
Choi JungSee RemarksMay 17Sale48.253,000144,750136,077May 21 04:36 PM
Choi JungSee RemarksApr 17Option Exercise3.401,4004,760139,077Apr 19 04:05 PM
Choi JungSee RemarksApr 17Sale45.503,000136,500137,677Apr 19 04:05 PM
Choi JungSee RemarksMar 16Option Exercise3.401,4004,760140,677Mar 20 05:30 PM
Choi JungSee RemarksMar 16Sale54.153,000162,450139,277Mar 20 05:30 PM
Sham HingSee RemarksMar 07Option Exercise0.4910,7145,25098,215Mar 09 05:30 PM
Calhoun Lesley AnnSee RemarksMar 05Sale60.35995,975388Mar 05 05:00 PM
Choi JungSee RemarksFeb 16Option Exercise3.401,4004,760142,277Feb 21 06:10 PM
Choi JungSee RemarksFeb 16Sale62.953,000188,850140,877Feb 21 06:10 PM
Radovich PeterSee RemarksFeb 01Sale57.3081246,5286,817Feb 02 08:17 PM
Radovich PeterSee RemarksJan 23Option Exercise1.6130,00048,30033,581Jan 25 08:09 PM
Radovich PeterSee RemarksJan 23Sale60.0030,0001,800,0003,581Jan 25 08:09 PM
Choi JungSee RemarksJan 17Option Exercise3.401,4004,760137,778Jan 18 07:59 PM
Choi JungSee RemarksJan 17Sale52.853,000158,550134,778Jan 18 07:59 PM
Radovich PeterSee RemarksJan 10Option Exercise1.6115,00024,15017,684Jan 11 09:48 PM
Radovich PeterSee RemarksJan 10Sale50.0015,000750,0002,684Jan 11 09:48 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 19Buy38.00175,0006,650,0004,889,066Dec 19 08:22 PM
Choi JungSee RemarksDec 18Option Exercise3.401,4004,760136,655Dec 20 05:12 PM
Choi JungSee RemarksDec 18Sale36.553,000109,650135,255Dec 20 05:12 PM
Choi JungSee RemarksNov 17Option Exercise3.401,4004,760138,255Nov 21 04:30 PM
Choi JungSee RemarksNov 17Sale39.753,000119,250136,855Nov 21 04:30 PM
Radovich PeterSenior VP, OperationsOct 30Sale35.0012,500437,5000Oct 31 08:15 PM
HOMCY CHARLES JDirectorOct 27Sale34.0915,600531,77067,728Oct 27 05:15 PM
HOMCY CHARLES JDirectorOct 26Sale33.9354,4001,845,78183,328Oct 27 05:15 PM
Choi JungSee RemarksOct 17Option Exercise3.401,4004,760139,855Oct 18 06:19 PM
Choi JungSee RemarksOct 17Sale32.653,00097,950138,455Oct 18 06:19 PM
Choi JungSee RemarksSep 29Option Exercise3.401,4004,760141,455Oct 02 05:27 PM
Choi JungSee RemarksSep 29Sale30.003,00090,000140,055Oct 02 05:27 PM
Choi JungSee RemarksAug 31Option Exercise3.401,4004,760143,055Sep 05 06:36 PM
Radovich PeterSee RemarksAug 31Sale30.002,41072,3002,684Sep 05 06:37 PM
Choi JungSee RemarksAug 31Sale30.003,00090,000141,655Sep 05 06:36 PM
Sham HingSee RemarksAug 02Option Exercise0.4921,42810,50081,504Aug 03 04:36 PM
PATRICK DEVAL LDirectorJul 25Option Exercise11.9727,053323,73027,053Jul 27 05:49 PM
PATRICK DEVAL LDirectorJul 25Sale29.6927,053803,2040Jul 27 05:49 PM
Choi JungSee RemarksJul 21Option Exercise3.401,4004,760144,655Jul 25 07:02 PM
Choi JungSee RemarksJul 21Sale30.003,00090,000143,255Jul 25 07:02 PM